Taisho Pharmaceutical Management Offers Buyout at 55% Premium
Taisho Pharmaceutical Co.'s pabron rhinitis capsules.
Photographer: Kiyoshi Ota/Bloomberg
This article is for subscribers only.
Taisho Pharmaceutical Holdings Co.’s management has made a tender offer to take the Japanese drugmaker private, with a proposal to buy the shares at a 55% premium to their latest closing price, the company said.
The tender period for the management buyout offer at ¥8,620 a share will be from Nov. 27 to Jan. 15, Taisho said in a statement Friday. The entity making the offer is a company owned by Executive Vice President Shigeru Uehara.